Azitra, Inc.
ATR-04
EGFRi-associated skin rash
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for ATR-04 in EGFRi-associated skin rash are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 17h ago
“Topline data from first cohort of Phase 1/2 trial expected in H2-2026.”